P3 Health Partners (PIII) Competitors $8.77 +0.01 (+0.11%) Closing price 09/5/2025 03:57 PM EasternExtended Trading$8.91 +0.15 (+1.65%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PIII vs. XGN, DCGO, CORBF, SERA, QIPT, BNR, EUDA, ATPC, BDSX, and BMGLShould you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include Exagen (XGN), DocGo (DCGO), Global Cord Blood (CORBF), Sera Prognostics (SERA), Quipt Home Medical (QIPT), Burning Rock Biotech (BNR), EUDA Health (EUDA), Agape ATP (ATPC), Biodesix (BDSX), and Basel Medical Group (BMGL). These companies are all part of the "healthcare" industry. P3 Health Partners vs. Its Competitors Exagen DocGo Global Cord Blood Sera Prognostics Quipt Home Medical Burning Rock Biotech EUDA Health Agape ATP Biodesix Basel Medical Group Exagen (NASDAQ:XGN) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Which has preferable valuation and earnings, XGN or PIII? Exagen has higher earnings, but lower revenue than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExagen$55.64M3.82-$15.11M-$0.89-10.87P3 Health Partners$1.50B0.04-$135.85M-$46.01-0.19 Do analysts rate XGN or PIII? Exagen currently has a consensus target price of $11.25, suggesting a potential upside of 16.34%. P3 Health Partners has a consensus target price of $16.25, suggesting a potential upside of 85.29%. Given P3 Health Partners' higher probable upside, analysts plainly believe P3 Health Partners is more favorable than Exagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00P3 Health Partners 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is XGN or PIII more profitable? P3 Health Partners has a net margin of -9.99% compared to Exagen's net margin of -28.85%. Exagen's return on equity of -130.38% beat P3 Health Partners' return on equity.Company Net Margins Return on Equity Return on Assets Exagen-28.85% -130.38% -34.69% P3 Health Partners -9.99%-183.60%-17.83% Do insiders & institutionals hold more shares of XGN or PIII? 75.3% of Exagen shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 12.6% of Exagen shares are owned by company insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor XGN or PIII? In the previous week, P3 Health Partners had 2 more articles in the media than Exagen. MarketBeat recorded 3 mentions for P3 Health Partners and 1 mentions for Exagen. Exagen's average media sentiment score of 1.47 beat P3 Health Partners' score of 1.15 indicating that Exagen is being referred to more favorably in the media. Company Overall Sentiment Exagen Positive P3 Health Partners Positive Which has more volatility & risk, XGN or PIII? Exagen has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. SummaryExagen beats P3 Health Partners on 9 of the 16 factors compared between the two stocks. Get P3 Health Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PIII vs. The Competition Export to ExcelMetricP3 Health PartnersMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.99M$2.09B$5.77B$9.91BDividend YieldN/AN/A6.71%4.52%P/E Ratio-0.1938.2075.5426.08Price / Sales0.049.34480.4288.33Price / CashN/A52.8536.9659.01Price / Book0.8311.1511.446.09Net Income-$135.85M-$63.67M$3.28B$266.14M7 Day Performance5.92%-1.25%0.96%0.34%1 Month Performance29.35%6.08%7.83%4.42%1 Year Performance-61.87%37.17%62.64%26.17% P3 Health Partners Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PIIIP3 Health Partners3.2148 of 5 stars$8.77+0.1%$16.25+85.3%-63.2%$62.99M$1.50B-0.19500Positive NewsShort Interest ↓XGNExagen4.5963 of 5 stars$9.86+1.2%$11.25+14.1%+182.7%$216.96M$55.64M-11.08220News CoveragePositive NewsShort Interest ↓DCGODocGo2.5914 of 5 stars$1.56-4.3%$3.59+130.1%-56.6%$152.58M$616.55M-8.214,407Positive NewsCORBFGlobal Cord BloodN/A$1.05flatN/AN/A$127.63M$196.12M0.001,200SERASera Prognostics1.3741 of 5 stars$3.23+4.9%N/A-53.7%$121.68M$80K-3.80120Short Interest ↓QIPTQuipt Home Medical2.6864 of 5 stars$2.63flat$3.15+19.8%-4.8%$114.26M$245.91M-10.961,200BNRBurning Rock Biotech0.6105 of 5 stars$8.55+3.2%N/A+76.5%$93.52M$70.67M-4.531,390Gap UpEUDAEUDA Health0.5197 of 5 stars$2.06-6.8%N/A-61.0%$76.54M$4.01M0.002News CoverageShort Interest ↑ATPCAgape ATP0.748 of 5 stars$1.31-2.6%N/A-29.1%$65.51M$1.32M-3.2040Positive NewsShort Interest ↓Gap UpBDSXBiodesix3.4489 of 5 stars$0.43-4.4%$1.75+310.2%-76.1%$62.55M$71.32M-1.47220News CoveragePositive NewsInsider TradeHigh Trading VolumeBMGLBasel Medical GroupN/A$2.04+3.0%N/AN/A$37.65MN/A0.0036 Related Companies and Tools Related Companies XGN Competitors DCGO Competitors CORBF Competitors SERA Competitors QIPT Competitors BNR Competitors EUDA Competitors ATPC Competitors BDSX Competitors BMGL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PIII) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding P3 Health Partners Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share P3 Health Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PIII Stock Alerts